KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Jazz Pharmaceuticals (JAZZ) FCF Margin (2016 - 2025)

Jazz Pharmaceuticals has reported FCF Margin over the past 16 years, most recently at 30.26% for Q4 2025.

  • For Q4 2025, FCF Margin fell 515.0% year-over-year to 30.26%; the TTM value through Dec 2025 reached 11.16%, down 2221.0%, while the annual FY2025 figure was 11.66%, 2171.0% down from the prior year.
  • FCF Margin for Q4 2025 was 30.26% at Jazz Pharmaceuticals, down from 42.15% in the prior quarter.
  • Over five years, FCF Margin peaked at 46.55% in Q1 2021 and troughed at 72.23% in Q2 2025.
  • A 5-year average of 25.35% and a median of 31.17% in 2022 define the central range for FCF Margin.
  • Biggest five-year swings in FCF Margin: skyrocketed 2658bps in 2022 and later crashed -10527bps in 2025.
  • Year by year, FCF Margin stood at 18.71% in 2021, then surged by 83bps to 34.21% in 2022, then plummeted by -55bps to 15.54% in 2023, then soared by 128bps to 35.41% in 2024, then dropped by -15bps to 30.26% in 2025.
  • Business Quant data shows FCF Margin for JAZZ at 30.26% in Q4 2025, 42.15% in Q3 2025, and 72.23% in Q2 2025.